Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Cancer cases in India estimated to reach 1.57 million in 2025
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Subscribe To Our Newsletter & Stay Updated